N,N-Dimethyltryptamine for Brain Activity Study

YE
Overseen ByYasmeen Esshaki
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Jon Dean
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This study examines how the psychedelic substance DMT affects the human brain when administered by the intravenous (IV) route. DMT is a naturally occurring chemical in the body that is thought to help improve mood when ingested in a continuously monitored medical setting. Previous research has shown that a single IV injection of DMT can be given safely, but its effects, which include changes in perception, emotions, and thinking, usually wear off within 15-20 minutes.

To better understand what happens when DMT's effects last longer, researchers have developed a method to give DMT slowly and continuously through an IV, which safely extends its effects for up to an hour or more. In this study, healthy volunteers who have prior experience using DMT will receive low and medium doses of DMT in this extended manner through an IV for 1 hour while undergoing a brain scanning technique known as functional magnetic resonance imaging (fMRI). These scans allow researchers to see changes in brain activity and blood flow in real time.

Participants will complete psychological assessments before and after receiving DMT, and additional brain scans without DMT will be used for comparison. The researchers will also use advanced computer techniques to help identify brain patterns linked to the visual experiences people report during DMT.

Overall, the goal of the study is to better understand how DMT affects the brain during an extended experience and to learn more about the biological processes behind its psychological effects.

Who Is on the Research Team?

JD

Jon Dean, PhD

Principal Investigator

UCSD

Are You a Good Fit for This Trial?

This trial is for healthy adults who have previously used DMT. Participants should not have any major medical or psychiatric conditions and must be able to safely undergo MRI scans.

Inclusion Criteria

Willing to refrain from smoking or use of nicotine from 8:00 AM on the morning of drug sessions until discharge at the end of the session
Able to fluently communicate in English
Willing to refrain from consumption of illicit psychoactive substances during the study
See 12 more

Exclusion Criteria

Positive urine drug screen for amphetamines, barbiturates, buprenorphine, cocaine, methamphetamine, MDMA, methadone, opiates, or phencyclidine
My liver is severely impaired.
First-degree relative with bipolar disorder, schizophrenia, or other psychotic disorder
See 28 more

What Are the Treatments Tested in This Trial?

Interventions

  • N,N-Dimethyltryptamine (DMT)

Trial Overview

Researchers are studying how low (15 mg) and medium (17.5 mg) doses of DMT, given slowly through an IV over one hour, affect brain activity using MRI scans in healthy volunteers with prior DMT experience.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: DMT hemifumarate "medium" doseExperimental Treatment1 Intervention
Group II: DMT hemifumarate "low" doseExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Jon Dean

Lead Sponsor